jiayi-li23/proxann_data huggingface dataset:
Bill 114-HR-4396 — Health / Drug and Alcohol Abuse
Subject: Health

Heroin and Prescription Drug Abuse Prevention and Reduction Act

This bill amends the Controlled Substances Act to revise requirements for and limitations on practitioners who dispense narcotic drugs for maintenance or detoxification treatment.

The Department of Health and Human Services (HHS) must establish grant programs to: (1) encourage prescribing and purchase of opioid overdose reversal drugs (e.g., naloxone), and (2) develop prescribing guidelines for such drugs. (Opioids are drugs with effects similar to opium, such as heroin or certain pain medications.)

The Centers for Disease Control and Prevention must provide support to improve drug overdose surveillance and reporting capabilities.

HHS may support syringe exchange programs.

The Substance Abuse and Mental Health Services Administration must provide support to: (1) reduce drug overdose deaths; and (2) develop, expand, and enhance substance use recovery support services.

This bill amends the Public Health Service Act to extend residential treatment programs for pregnant and postpartum women.

The Center for Substance Abuse Treatment must: (1) carry out a pilot program to support services for pregnant and postpartum women with a substance use disorder; (2) award grants to expand treatment activities in areas with a high rate of, or a rapid increase in, the use of opioids; and (3) support increasing the capacity of substance use disorder services for adolescents.

This bill amends the Employee Retirement Income Security Act of 1974 (ERISA) and Internal Revenue Code to direct HHS and the Departments of Labor and the Treasury to require disclosures, issue guidance, conduct audits, and publish information regarding the requirement for group health plans and health insurance coverage to have parity between mental health and substance use disorder benefits and medical and surgical benefits. HHS must establish a consumer parity portal website.

HHS must establish a loan repayment program for substance use disorder health professionals.
Bill 114-HR-4635 — Health / Drug and Alcohol Abuse
Subject: Armed forces and national security

Servicemembers and Veterans Prescription Drug Safety Act of 2016

 This bill directs the Department of Defense (DOD) and the Department of Justice (DOJ) to carry out a joint program under which an eligible person who has lawfully obtained a covered controlled substance may deliver it for disposal at a facility to be specified by DOD and DOJ.

An eligible person for this purpose shall be:

 a member of the Armed Forces, an individual receiving or entitled to military retired or retainer pay, a member's dependent-beneficiary who is receiving certain health care services, or any person lawfully entitled to dispose of the property of any of such individuals who dies in lawful possession of a controlled substance for personal use. DOD and DOJ shall develop guidelines and procedures to prevent the diversion, misuse, theft, or loss of such substances delivered under the program.

DOJ and the Department of Veterans Affairs (VA) shall carry out a similar joint program covering any veteran, veteran's spouse or dependent, a person in receipt of medical services at a VA facility, or any person lawfully entitled to dispose of the property of any of such individuals who dies in lawful possession of a controlled substance for personal use.

DOJ and the VA shall also develop guidelines and procedures to prevent the diversion, misuse, theft, or loss of such substances delivered under the program.
Bill 114-HR-4697 — Health / Drug and Alcohol Abuse
Subject: Health

Prevent Drug Addiction Act of 2016

This bill amends the Public Health Service Act to require the Substance Abuse and Mental Health Services Administration (SAMHSA) to award grants for consumer education about opioid addiction. (Opioids are drugs with effects similar to opium, such as heroin or certain prescription painkillers.)

This bill amends the Controlled Substances Act to require medical practitioners to be trained in the treatment of opioid-dependent patients, pain management, and early detection of opioid addiction before they can be registered by the Drug Enforcement Administration to dispense opioids.

Opioid treatment programs that close on any day must make arrangements for each patient to receive treatment during the closure, as necessary.

A report must be submitted to SAMHSA for each individual who dies while receiving treatment in an opioid treatment program. In states receiving funding for controlled substance monitoring programs, deaths where an opioid drug is detected in the body must be reported to SAMHSA.

The National Center for Health Statistics of the Centers for Disease Control and Prevention must establish a National Opioid Death Registry to track opioid-related deaths.

The Agency for Healthcare Research and Quality must develop and apply prescription drug addiction prevention and treatment quality measures.

This bill amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act to allow prescription drug plan (PDP) sponsors to limit the access of certain beneficiaries to addictive drugs. PDP sponsors must have a utilization management tool to prevent drug addiction.

Medicare Drug Integrity Contractors may accept prescription and medical records to determine whether a beneficiary is at risk for prescription drug addiction.
Bill 114-HR-4876 — Health / Drug and Alcohol Abuse
Subject: Health

Medicare Prescription Drug Abuse Prevention Act of 2016

This bill amends title XVIII (Medicare) of the Social Security Act to: (1) authorize a Medicare prescription drug plan (PDP) sponsor to establish a drug management program under which the PDP sponsor may limit an at-risk beneficiary's access to coverage for frequently abused drugs to include only those drugs that are prescribed by selected prescribers and dispensed by selected pharmacies; and (2) require a PDP sponsor to have in place a utilization management tool to prevent drug abuse.

With respect to a drug management program, a PDP sponsor must: (1) provide specified notice to a beneficiary who has been identified by the Centers for Medicare & Medicaid (CMS) as "at-risk" and consequently enrolled in the program; and (2) in selecting prescribers and dispensers, ensure that the beneficiary continues to have reasonable access to drugs. These determinations shall be subject to expedited reconsideration and appeal. A PDP sponsor must review and consider an at-risk beneficiary's preferences regarding prescriber and pharmacy selection.

Certain individuals, including those receiving hospice care or residing in a long-term care facility, are exempted from enrollment in a drug management program.

CMS must, for purposes of quality or performance assessments, review and consider complaints received from at-risk beneficiaries regarding lack of access due to their enrollment in a drug management program. In addition, CMS must establish rules and procedures requiring a PDP sponsor to provide specified program data.
Bill 114-HR-4969 — Health / Drug and Alcohol Abuse
Subject: Health

(This measure has not been amended since it was reported to the House on May 10, 2016. The summary of that version is repeated here.)

John Thomas Decker Act of 2016

(Sec. 2) This bill amends the Public Health Service Act to require the Department of Health and Human Services (HHS) to report on the availability of information regarding prescription of opioids after youth sports injury, including information on opioid use and misuse, injury treatments that do not involve opioids, and treatment for opioid addiction. (Opioids are drugs with effects similar to opium, such as heroin and certain pain medications.) The report must determine the extent this information is available to teenagers and adolescents who play youth sports, their families, youth sports groups, and health care providers.

Taking into consideration the findings of the report, HHS must develop and disseminate such information.
Bill 114-HR-5020 — Health / Drug and Alcohol Abuse
Subject: Health

Synthetic Drug Awareness Act of 2016

This bill requires the Surgeon General to report to Congress on the public health effects of the increased use since January 2010 by individuals who are 12 to 18 years old of drugs developed and manufactured to avoid control under the Controlled Substances Act (e.g., synthetic marijuana, also known as "spice," and synthetic amphetamines, also known as "bath salts").
Bill 114-HR-5052 — Health / Drug and Alcohol Abuse
Subject: Crime and law enforcement

Opioid Program Evaluation Act or the OPEN Act

(Sec. 2) This bill directs the Department of Justice (DOJ) to enter into an arrangement with the National Academy of Sciences (NAS) to identify outcomes and develop metrics to evaluate: (1) the incidence of opioid abuse and illegal opioid distribution, and (2) the effectiveness of a DOJ grant program to provide opioid abuse services.

DOJ must publish outcomes and metrics and require grant recipients to collect and report data. The NAS must publish the evaluations.

(Sec. 3) Additionally, the bill directs the Department of Health and Human Services (HHS) to enter into an arrangement with the NAS to identify outcomes and develop metrics to evaluate: (1) the incidence of opioid abuse and illegal opioid distribution, and (2) the effectiveness of HHS grant programs to address opioid abuse.

HHS must publish outcomes and metrics and require grant recipients to collect and report data. The NAS must publish the evaluations.

(Sec. 6) It amends the Justice Assistance Act of 1984 to reduce for FY2022 the authorization of appropriation for financial assistance under the Emergency Federal Law Enforcement Assistance program.
Bill 114-HR-5095 — Health / Drug and Alcohol Abuse
Subject: Health

Prescriber Support Act of 2016

This bill amends the Public Health Service Act to authorize the Department of Health and Human Services (HHS) to award grants to states for systems that help prescribers: (1) treat and manage patient pain; and (2) prevent, identify, and respond to patient substance misuse and substance abuse disorders. In awarding grants, HHS must give priority to states with the greatest need.
Bill 114-HR-5216 — Health / Drug and Alcohol Abuse
Subject: Health

Opioid and Heroin Abuse Crisis Investment Act of 2016

This bill appropriates funding for the activities in the bill.

This bill amends the Public Health Service Act to require the Department of Health and Human Services to enter into cooperative agreements with states to expand opioid treatment capacity, make services more affordable to those who cannot afford them, and help individuals seek treatment, successfully complete treatment, and sustain recovery. (Opioids are drugs with effects similar to opium, such as heroin and certain pain medications.) Funding must be allocated to states based on the severity of the opioid epidemic in the state and the strength of the state's strategy to respond.

The Office of the National Coordinator for Health Information Technology must expand efforts to support prescription drug monitoring programs and health information technology interoperability.

The Bureau of Prisons must support drug treatment programs.

The bill amends the Second Chance Act to require the Department of Justice (DOJ) to help justice-involved individuals successfully reintegrate into the community.

The bill amends the Controlled Substances Act to permit DOJ to support the development of residential and aftercare services for substance-involved inmates.

DOJ must establish new heroin enforcement groups within the Drug Enforcement Administration to target, disrupt, and dismantle heroin trafficking organizations.
Bill 114-HR-5287 — Health / Drug and Alcohol Abuse
Subject: Health

Medicaid Coverage for Addiction Recovery Expansion Act

This bill amends title XIX (Medicaid) of the Social Security Act to allow states to provide medical assistance to adults for residential addiction treatment facility services under the Medicaid program. "Residential addiction treatment facility services" are medically necessary inpatient services provided in an accredited, size-limited facility for the purpose of treating a substance use disorder within a specified time period.

The provision of medical assistance for such services to an individual shall not prohibit federal financial participation for medical assistance with respect to other services provided to the individual within the same time period.

Subject to specified conditions, a woman who is eligible for medical assistance on the basis of being pregnant may remain eligible for residential addiction treatment facility services for specified time periods without regard to eligibility limits that would otherwise apply as a result of her pregnancy ending.

In addition, the bill establishes a grant program for states to expand infrastructure and treatment capabilities of existing youth addiction treatment facilities that: (1) provide addiction treatment services to youths under Medicaid or the Children's Health Insurance Program (CHIP), and (2) are located in communities with high numbers of medically underserved populations of at-risk youths. At least 15% of grant funds awarded to a state must be used for making payments to rural facilities.
Bill 114-HR-5432 — Health / Drug and Alcohol Abuse
Subject: Health

Stem the Tide of Overdose Prevalence from Opiate Drugs Act of 2016 or as the STOP OD Act of 2016

This bill permits the Centers for Disease Control and Prevention (CDC) to award grants: (1) to expand educational efforts to prevent abuse of opioids, which are drugs with effects similar to opium, such as heroin; (2) to promote treatment of persons who abuse opioids; and (3) to promote understanding of addiction.

The Department of Health and Human Services (HHS) may award grants to: (1) support first responders carrying and administering naloxone, which is a prescription drug used to rapidly reverse an opioid overdose; (2) establish processes for referral to treatment for opioid abuse; and (3) reimburse for testing for fentanyl in opioid overdoses and reporting the results to the CDC.

This bill amends the Controlled Substances Act to impose a fee on persons convicted of drug offenses. Collected amounts are made available for the HHS grants in this bill.

Specified agencies must submit to the Office of E-Government and Information Technology of the Office of Management and Budget an inventory of agency data centers and a strategy to consolidate and optimize the data centers.

The bill revises reporting requirements for the Department of Defense (DOD) regarding data centers. DOD and the Director of National Intelligence may waive this bill's data center requirements for any national security system.

The bill sets forth requirements for the Office of E-Government and Information Technology, including that the office must publish a goal for cost savings and optimization.

The bill's provisions regarding data centers are repealed at the start of FY2021.
Bill 114-HR-5655 — Health / Drug and Alcohol Abuse
Subject: Health

Addiction Prevention and Responsible Opioid Practices Act

This bill addresses prescription opioid misuse.

 The Food and Drug Administration (FDA) must: (1) seek recommendations concerning opioid drugs from an FDA advisory committee relating to the approval of a new drug that is an opioid, and the labeling of opioid drugs for pediatric prescriptions; (2) develop recommendations for education programs for prescribers of opioids; and (3) issue guidance for labeling that deters opioid abuse.

The bill amends the Federal Food, Drug, and Cosmetic Act by requiring manufacturers of opioid drugs to ensure that certain information about the risk factors associated with opioid drugs are included on the drug labels.

The bill amends the Controlled Substances Act by: (1) addressing annual narcotic manufacturing quotas with respect to fentanyl, oxycodone, hydrocodone, oxymorphone, and hydromorphone; and (2) directing the Department of Justice (DOJ) to require medical practitioners to complete a training program on prescribing opioids for chronic pain before they are certified to prescribe controlled substances in schedule II, III, or IV.

The bill establishes requirements for prescription drug monitoring systems to prevent over-prescribing controlled substances.

The Department of Health and Human Services must: (1) submit a plan of action for addressing outliers in opioid prescribing practices and ensuring an adequate response to protect the public health, and (2) study the expansion of Medicare coverage for alternatives to opioid treatments.

The bill amends the Internal Revenue Code to impose an excise tax on manufacturers or producers of opioid pain relievers. A portion of the amount generated from the tax must be used for substance abuse treatment programs.

DOJ must establish a take-back program for the safe and environmentally responsible disposal of controlled substances.
Bill 114-HR-5842 — Health / Drug and Alcohol Abuse
Subject: Armed forces and national security

Helping Our Veterans with Chronic Pain and Opioid Addiction Act of 2016

This bill requires the Department of Veterans Affairs (VA) to conduct a three-year pilot program to provide health and social services and coordination of care and case management to covered veterans in need of treatment for opioid addiction and chronic pain through VA facilities and through qualified non-VA health care providers.

A "covered veteran" is a veteran who is enrolled in the veterans' health care system and eligible for hospital, nursing home, and domiciliary care under such system.

The pilot program shall be carried out in at least five different states with VA medical facilities that demonstrate: (1) the need for additional resources to provide health care services to veterans for opioid abuse, (2) the highest rates per capita of opioid addiction in the United States, and (3) a lack of sufficient VA capacity to meet the demand for such treatment.

Under such program, the VA: (1) may enter into contracts with non-VA providers to provide health care services to veterans,  and (2) shall provide for the exchange of medical information between the VA and any such provider.

The VA shall conduct concurrent assessments of its capabilities and the capabilities of community providers to provide health care services for the treatment of veterans with opioid dependency abuse or chronic pain.

The VA shall: (1) require all appropriate VA health care facilities and all VA facilities providing mental health and social services to veterans to have a supply of naloxone or other medication for reversing opioid overdose, and (2) ensure that all appropriate employees at such facilities receive training on the administration of such medication.
Bill 114-HR-5956 — Health / Drug and Alcohol Abuse
Subject: Health

Youth Opioid Use Treatment Help Act of 2016 or the YOUTH Act

This bill amends the Public Health Service Act to revise and reauthorize through FY2022 grants for substance abuse treatment services for children and adolescents. The grant program is expanded to cover young adults.

The Agency for Healthcare Research and Quality (AHRQ) must award grants for demonstration programs to: (1) expand access to medication-assisted treatment for opioid use disorders among adolescents and young adults, or (2) create and distribute for pediatric health care providers resources on medication-assisted treatment training and implementation.

AHRQ must report on the demonstration programs and the availability of medication-assisted treatment for adolescents and young adults. The report must include recommendations for ensuring such treatment is accessible.

The Government Accountability Office must study how federal agencies are addressing substance use and substance use disorders among adolescents and young adults.
Bill 114-HR-6243 — Health / Drug and Alcohol Abuse
Subject: Crime and law enforcement

Comprehensive Fentanyl Control Act

This bill amends the Controlled Substances Act (CSA) to modify the definition of "controlled substance analogue" to mean a substance that has a similar (previously, substantially similar) chemical structure and pharmacological effect to a schedule I controlled substance.

 Additionally, it modifies the treatment of controlled substance analogues. Under current law, a controlled substance analogue that is intended for human consumption is treated as a schedule I controlled substance. This bill replaces the "intended for human consumption" qualifier with a "not a chemical substance subject to the Toxic Substances Control Act" qualifier. Specifically, a controlled substance analogue that is not a chemical substance under the Toxic Substances Control Act is treated as a schedule I controlled substance.

 The bill modifies the drug quantity thresholds that trigger a mandatory minimum prison term for a defendant who manufactures, distributes, or possesses with intent to distribute fentanyl.

It also establishes a consecutive mandatory prison term for a defendant who commits a drug offense involving a detectable amount of heroin or fentanyl.

The bill allows the Drug Enforcement Administration to temporarily place a substance into schedule I if it reasonably believes that the substance: (1) is a synthetic opioid analgesic; (2) is the object of clandestine importation, manufacture, or distribution; and (3) poses an imminent hazard to public health and safety. Finally, the bill makes it a crime to knowingly mail to an unauthorized person equipment that may be used to manufacture counterfeit controlled substances.
Bill 114-HR-6262 — Health / Drug and Alcohol Abuse
Subject: Taxation

Addiction Recovery through Family Health Accounts Act 

This bill amends the Internal Revenue Code to permit taxpayers to use tax-favored health reimbursement arrangements, health flexible spending arrangements, health savings accounts, and Archer medical savings accounts to pay for alcohol and drug addiction treatments for specified family members as if the expenses were incurred for a dependent.
Bill 114-HR-6263 — Health / Drug and Alcohol Abuse
Subject: Taxation

Addiction Recovery through Family Deductions Act 

This bill amends the Internal Revenue Code to expand certain deductions and exclusions to include expenses related to alcohol and drug addiction treatments for specified family members who are not dependents.

The bill allows the expenses to be treated as: (1) medical care for the purpose of the deduction for medical care, and (2) qualified Indian health care benefits for the purpose of the exclusion from gross income of the value of any qualified Indian health care benefit.

The bill also allows insurance covering alcohol and drug addiction treatment for the non-dependent family members to be treated as insurance that constitutes medical care for the purpose of the deduction for health-insurance costs of self-employed individuals.